Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032
Overview
The Norway Pharmacogenetics Testing in Psychiatry-Depression Market is expected to reach a 16.40 USD Billion by 2032 and is projected to grow at a CAGR of 7.82% from 2025 to 2032.
Revenue, 2024 (USD Billion)
10.39
Forecast, 2032 (USD Billion)
16.40
CAGR, 2024 - 2032
7.82%
Report Coverage
Norway
Norway Pharmacogenetics Testing in Psychiatry-Depression Market 2018-2032 USD Billion
Norway Pharmacogenetics Testing in Psychiatry-Depression Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 10.39 USD Billion
- Projected Market Size (2032): 16.40 USD Billion
- CAGR (2025-2032): 7.82%
Key Findings of Norway Pharmacogenetics Testing in Psychiatry-Depression Market
- The Norway Pharmacogenetics Testing in Psychiatry-Depression Market was valued at 10.39 USD Billion in 2024.
- The Norway Pharmacogenetics Testing in Psychiatry-Depression Market is likely to grow at a CAGR of 7.82% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Whole Genome Sequencing in Test Segment accounted for the largest share of the market with a revenue of 10.93 USD Billion
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 11.60% during the forecast period from 2024 to 2032.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Scope
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Product
- Software and Services
- Instruments
- Consumables
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
Gene
- COMT
- MTHFR
- SLC6A4
- Others
- CYP3A4
- HLA-A
- HTR2A/C
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
End User
- Others
- Academic And Research Institutes
- Diagnostics Laboratories
- Hospital and Clinics
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
Patient
- Child
- Geriatric
- Adult
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 10.39 USD Billion |
| Market Value in 2032 | 16.40 USD Billion |
| CAGR (2025-2032) | 7.82% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Type,Product,Test, Gene,End User,Distribution Channel,Patient |
Regional Insights:
-
Leading Market (2024-2032): Norway, leading in terms of revenue 10.39 USD Billion in 2024
- Key Country: Norway, leading in terms of revenue with value of 10.39 USD Billion in 2024.
Segments and Scope
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Type
- Anxiety is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 3.67 USD Billion in the year 2024.
- Anxiety is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 10.33 % in forecast period 2025-2032.
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Product
- Consumables is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 5.31 USD Billion in the year 2024.
- Consumables is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.82 % in forecast period 2025-2032.
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Test
- Whole Genome Sequencing is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 10.93 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 10.87 % in forecast period 2025-2032.
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Gene
- CYP2C19 is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 2.46 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 11.60 % in forecast period 2025-2032.
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By End User
- Academic And Research Institutes is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 4.86 USD Billion in the year 2024.
- Academic And Research Institutes is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.39 % in forecast period 2025-2032.
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 5.25 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 8.62 % in forecast period 2025-2032.
-
Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Patient
- Adult is the largest segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 5.53 USD Billion in the year 2024.
- Adult is the Fastest growing segment in Norway Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.31 % in forecast period 2025-2032.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| Qiagen | |||
| Sonic Healthcare Limited | |||
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Geographical Sales Distribution, 2018-2032 USD Billion
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Norway Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Product,Test, Gene,End User,Distribution Channel,Patient.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 10.39(Revenue in USD Billion) in 2022.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 7.82% during the forecast period of 2024 to 2032.
The Whole Genome Sequencing segment is expected to dominate the Norway Pharmacogenetics Testing in Psychiatry-Depression Market, holding a largest market share of 10.93 USD Billion in 2024
Coming Soon....
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Scope
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Product
- Software and Services
- Instruments
- Consumables
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
Gene
- COMT
- MTHFR
- SLC6A4
- Others
- CYP3A4
- HLA-A
- HTR2A/C
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
End User
- Others
- Academic And Research Institutes
- Diagnostics Laboratories
- Hospital and Clinics
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
Patient
- Child
- Geriatric
- Adult
Frequently Asked Questions
The Norway Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Product,Test, Gene,End User,Distribution Channel,Patient.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 10.39(Revenue in USD Billion) in 2022.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 7.82% during the forecast period of 2024 to 2032.
The estimated market value of the Norway Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 16.40 (USD Billion).
Norway Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Frequently Asked Questions
The Norway Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Product,Test, Gene,End User,Distribution Channel,Patient.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 10.39(Revenue in USD Billion) in 2022.
Norway Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 7.82% during the forecast period of 2024 to 2032.
The estimated market value of the Norway Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 16.40 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.